ALERT! ELTP .09-Elite-Pharmaceutical-CONFERENCE CA
Post# of 94145
ALERT! ELTP .09-Elite-Pharmaceutical-CONFERENCE CALL and EARNINGS-PR-EXPECTED-TOMORROW...
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has five commercial products with five additional products under review, pending approval by the FDA.
Elite’s lead pipeline products include abuse resistant opioids utilizing the Company’s patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.
Elite also has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories.
Elite operates a FDA GMP(Good Manufacturing Practices) and DEA registered facility for research, development, and manufacturing located in Northvale, NJ
(0)
(0)